• Antios Therapeutics raises $25 million for potential HBV curative therapy

    6 monthes ago - By Healio

    Antios Therapeutics completed a $25 million oversubscribed Series A financing to develop ATI-2173, an oral drug candidate for treating patients with hepatitis B and potentially coinfected with hepatitis D, according to a press release.
    “The next frontier in virology is to cure hepatitis B,” Abel de la Rosa, PhD, co-founder and CEO of Antios, said in the release. “The strong financial support from our investors along with their extensive experience in clinical development and success building innovative companies in the infectious disease field will enable us to accelerate the
    Read more ...